• Heba F. Salem Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Egypt
  • Sabry M. Tamam Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Egypt
  • Sahar M. Lotayef Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Egypt


Objective: Gold nanoparticles and nanoliposomes are effective new technology in delivering the bioactive agents and enhancing their performance by increasing the bioavailability. The goal of the present study was the formulation of liposome for the use as a carrier for nanogold conjugated with acyclovir (ACV), an antiviral drug, to enhance ACV delivery.

Methods: The gold nanoparticles were used as a capping agent for ACV and sodium citrate was used as reducing agent for the gold. Transmission electron microscopy was used for characterization and to study the morphological and structural properties of drug-metallic nanostructures. Nanoliposomes were formulated using different molar ratios of a positive charge inducer (stearyl amine) or a negative charge inducer (diacetyl phosphate), lecithin, cholesterol and Span 60.

Results: Gold nanoparticles with a particle size of 10–20 nm were formed. This small size of the formed particles has a clear effect in reducing the gold nanoparticles toxicity and enhancing the cellular uptake. The amount of sodium citrate used in this preparation influences the size of the gold nanoparticle. The present study employed 1% trisodium citrate that contains a carboxylic group and this carboxylic group works as a reducing and capping agent to synthesize ACV-gold nanoparticles conjugate. Liposomal formula F6 had the highest entrapment efficiency approaching 42%, the low particle size of 160 nm, and zeta potential of 43.5 mV.

Conclusion: It is evident from the study that the liposomes can be used as a carrier of ACV conjugated with gold nanoparticles. This new strategy could be used successfully in the treatment of viral infection.

Keywords: Acyclovir, Gold Nanoparticles, Liposome, Dicetyl phosphate, Stearylamine


Download data is not yet available.


1. De Clercq E, HJ Field. Antiviral prodrugs–the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006;147:1-11.
2. Shah, PJ. Monitoring of Outpatient parenteral antimicrobial therapy (OPAT) and implementation of clinical pharmacy services at a community hospital infusion unit. J Pharm Pract 2015;28:462-8.
3. Luengo J. Preliminary pharmacokinetic study of different preparations of acyclovir with β‐cyclodextrin. J Pharm Sci Sci 2002;91:2593-8.
4. Attia IA. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. AAPS PharmSciTech 2007;8:206-12.
5. Kagan L, A Hoffman. Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations. Expert Opin Drug Delivery 2008;5:681-92.
6. Godin B, E Touitou. Ethosomes: new prospects in transdermal delivery. Crit Rev Ther Drug Carrier Syst 2003;20:63-102.
7. Sivakumar P, C Nethradevi, S Renganathan. Synthesis of silver nanoparticles using lantana camara fruit extract and its effect on pathogens. Asian J Pharm Clin Res 2012;5:97-101.
8. Mezei, M, V Gulasekharam. Liposomes-a selective drug delivery system for the topical route of administration I. Lotion dosage form. Life Sci 1980;26:1473-7.
9. Touitou E. Drug delivery across the skin. Expert Opin Biol Ther 2002;2:723-33.
10. Loth H. Vehicular influence on transdermal drug penetration. Int J Pharm 1991;68:1-10.
11. Masini V. Cutaneous bioavailability in hairless rats of tretinoin in liposomes or gel. J Pharm Sci 1993;82:17-21.
12. Naveena BE, S Prakash. Biological synthesis of gold nanoparticles using marine algae Gracilaria corticata and its application as a potent antimicrobial and antioxidant agent. Asian J Pharm Clin Res 2013;6:179-82.
13. Henglein A, M Giersig. Formation of colloidal silver nanoparticles: capping action of citrate. J Phys Chem B 1999; 103:9533-9.
14. Storhoff JJ. One-pot colorimetric differentiation of polynucleotides with single base imperfections using gold nanoparticle probes. J Am Chem Soc 1998;120:1959-64.
15. Zalba S. Application of different methods to formulate PEG-liposomes of oxaliplatin: evaluation in vitro and in vivo. Eur J Pharm Biopharm 2012;81:273-80.
16. Perugini P, F Pavanetto. Liposomes containing boronophenylalanine for boron neutron capture therapy. J Microencapsul 1998;15:473-83.
17. Hathout RM. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech 2007;8:E1-E12.
18. Srinath P, S Vyas, PV Diwan. Preparation and pharmacodynamic evaluation of liposomes of indomethacin.Drug Dev Ind Pharm 2000;26:313-21.
19. Nagarsenker M, VY Londhe, G Nadkarni. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm 1999;190:63-71.
20. Xu, X. Effect of sodium oleate adsorption on the colloidal stability and zeta potential of detonation synthesized diamond particles in aqueous solutions. Diamond Relat Mater 2005;14:206-12.
21. Riddick TM. Control of colloid stability through zeta potential. Blood 1968;10:12-41.
22. Tabrizi A, F Ayhan, H Ayhan. Gold nanoparticle synthesis and characterisation. Hacettepe J Biol Chem 2009;37:217-26.
23. Duangjit S. Role of the charge, carbon chain length, and content of surfactant on the skin penetration of meloxicam-loaded liposomes. Int J Nanomed 2014;9:2005-17.
24. Crommelin DJ. Influence of lipid composition and ionic strength on the physical stability of liposomes. J Pharm Sci 1984;73:1559-63.
25. Hosny KM. Ciprofloxacin as an ocular liposomal hydrogel. AAPS PharmSciTech 2010;11:241-6.
404 Views | 945 Downloads
How to Cite
Salem, H. F., S. M. Tamam, and S. M. Lotayef. “BIODEGRADABLE LIPOSOMES FOR ACYCLOVIR-GOLD NANOPARTICLES AS AN EFFICIENT CARRIERFOR ENHANCED TOPICAL DELIVERY”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 9, no. 8, Aug. 2017, pp. 60-64, doi:10.22159/ijpps.2017v9i8.17243.
Original Article(s)